- Home
- CNC vs DMAC Comparison
CNC vs DMAC Comparison
Compare CNC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNC
- DMAC
- Stock Information
- Founded
- CNC 1984
- DMAC 2000
- Country
- CNC United States
- DMAC United States
- Employees
- CNC N/A
- DMAC N/A
- Industry
- CNC Medical Specialities
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CNC Health Care
- DMAC Health Care
- Exchange
- CNC Nasdaq
- DMAC Nasdaq
- Market Cap
- CNC 14.3B
- DMAC 310.1M
- IPO Year
- CNC 2001
- DMAC N/A
- Fundamental
- Price
- CNC $32.00
- DMAC $6.87
- Analyst Decision
- CNC Hold
- DMAC Strong Buy
- Analyst Count
- CNC 16
- DMAC 3
- Target Price
- CNC $38.33
- DMAC $12.33
- AVG Volume (30 Days)
- CNC 13.8M
- DMAC 448.5K
- Earning Date
- CNC 10-24-2025
- DMAC 11-12-2025
- Dividend Yield
- CNC N/A
- DMAC N/A
- EPS Growth
- CNC N/A
- DMAC N/A
- EPS
- CNC 4.07
- DMAC N/A
- Revenue
- CNC $159,673,000,000.00
- DMAC N/A
- Revenue This Year
- CNC $30.26
- DMAC N/A
- Revenue Next Year
- CNC N/A
- DMAC N/A
- P/E Ratio
- CNC $7.87
- DMAC N/A
- Revenue Growth
- CNC 10.73
- DMAC N/A
- 52 Week Low
- CNC $25.08
- DMAC $3.19
- 52 Week High
- CNC $77.29
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- CNC 57.18
- DMAC 63.84
- Support Level
- CNC $28.24
- DMAC $6.83
- Resistance Level
- CNC $36.14
- DMAC $7.41
- Average True Range (ATR)
- CNC 1.20
- DMAC 0.43
- MACD
- CNC 0.45
- DMAC 0.03
- Stochastic Oscillator
- CNC 47.59
- DMAC 73.62
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.